MXCT vs NOC · rev $38.6M vs P/E 17, rev $41.95B
MaxCyte Inc (MXCT) versus Northrop Grumman Corporation (NOC) — a side-by-side from cached financials, not a winner call.
MaxCyte Inc (MXCT) is a medical devices company listed on NASDAQ.
Northrop Grumman Corporation (NOC) is a aerospace & defense company listed on NYSE.
Latest reported MXCT revenue for 2024-12-31 was $38.6M. Net income was -$41.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. MXCT currently screens at market cap $124.3M.
Latest reported NOC revenue for 2025-12-31 was $41.95B. Net income was $4.18B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. NOC currently screens at market cap $78.14B and trailing P/E 17.2.
MXCT currently screens at market cap $124.3M. NOC currently screens at market cap $78.14B and trailing P/E 17.2.
Not investment advice. Open the MXCT and NOC stock pages for the full models.
Not investment advice.